SIRT6: A Literature Course on What the Published Studies Report

This page is a structured reading guide to the published literature on SIRT6 (sirtuin 6). It describes what researchers studied, in which models, and what they reported — nothing more. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis or treatment. No protocol, dose or course of action is suggested anywhere on this page, and the papers summarised below were, with one primate exception, conducted in cultured cells and rodents.

Module 1: What SIRT6 Is and How It Has Been Studied

Definition and class

SIRT6 is one of seven mammalian sirtuins, a family of NAD+-dependent enzymes that act on acetylated and acylated protein substrates, including histones within chromatin. It is an endogenously expressed intracellular protein encoded by the SIRT6 gene, predominantly nuclear in localisation. It is therefore not a synthetic peptide, not an injectable product, and not a supplement ingredient in the studies collected here; it is a protein that researchers manipulate genetically or pharmacologically inside cells and animals in order to observe what changes.

Origin and the forms used in research

Because SIRT6 is a native enzyme, the "forms" encountered in the literature are experimental rather than commercial. The most common designs are: germline or tissue-specific knockout, in which the gene is deleted; conditional or inducible deletion in a single cell type; transgenic or vector-driven overexpression; small-molecule activation or inhibition in cultured cells; and comparison of SIRT6 levels between young, aged, or diseased tissue. A 2018 Nature report extended this beyond rodents by generating SIRT6-deficient cynomolgus monkeys, and the researchers reported developmental retardation in the deficient animals (PMID 30135584). A 2026 Aging Cell study examined SIRT6 at the subcellular level and reported that it regulates protein synthesis and folding through nucleolar remodeling (PMID 41703428).

Limits of the evidence in Module 1

The verified literature reviewed here contains no clinical trial of a SIRT6 product in humans, no description of a marketed SIRT6 compound, and no standard preparation that could be described in pharmaceutical terms. Statements about "SIRT6" in these papers refer to the enzyme's presence, absence or activity inside tissue, not to something administered to a person.

Module 2: Mechanism as Described in the Literature

Chromatin, transcription factors and downstream pathways

Across the verified papers, SIRT6 is consistently framed as an upstream regulator that changes the activity of specific transcriptional programmes. In a cardiomyocyte model of doxorubicin injury, researchers reported that SIRT6 activated PPARα and that this was associated with improvement in doxorubicin-induced myocardial cell aging and damage (PMID 38395252). In vascular smooth muscle cells studied in the context of chronic kidney disease, the study described protection from osteogenic transdifferentiation occurring via the transcription factor Runx2 (PMID 34793336).

Other mechanistic routes have been reported in different tissues. A 2017 Nature Communications paper reported that Sirt6 deficiency exacerbated podocyte injury and proteinuria through targeting Notch signalling (PMID 28871079). In a demyelination model, researchers reported that SIRT6 modulated the lesion microenvironment by targeting astrocytic CHI3L1 (PMID 39342313). A 2025 report described Sirt6 loss activating Got1 and facilitating cleft palate through abnormally activated glycolysis, linking the enzyme to metabolic control during craniofacial development (PMID 40050262).

Senescence as a recurring readout

Several groups used cellular senescence as the primary mechanistic endpoint. Researchers reported that SIRT6 protected smooth muscle cells from senescence and reduced atherosclerosis in their model (PMID 33353368), and a separate group reported that Sirt6 attenuated chondrocyte senescence and osteoarthritis progression (PMID 36496445). The 2026 nucleolar study added a proteostasis angle by reporting effects on protein synthesis and folding (PMID 41703428).

Limits of the evidence in Module 2

Mechanistic pathways were identified in defined systems — one cell type, one injury model, one species — and the papers do not establish that the same pathway dominates in other tissues or in humans. Where a mechanism was inferred from gene deletion, the finding describes what happens when SIRT6 is absent, which is not the same as demonstrating what increasing SIRT6 would do in intact tissue.

Module 3: Reported Outcomes by Study

The table below summarises the model, the endpoint examined, and the result as the authors described it. None of these are outcomes in humans, and none of them are presented here as a benefit that would transfer to a person.

Limits of the evidence in Module 3

Each row represents a single experimental programme, usually in one laboratory, with endpoints chosen to test a specific hypothesis. Positive findings in a disease model are not evidence of efficacy, and the verified set contains no randomised human trial, no dose-ranging work in people, and no comparison against an established treatment. Several of the results were produced by removing SIRT6 rather than by raising it, so the direction of any translational inference is uncertain.

Module 4: Sirt6 Side Effects: What Studies Report

Because SIRT6 was not administered as a drug in these papers, the published "adverse" findings are mostly the consequences of losing or inhibiting the enzyme, plus phenotypes observed in deficient animals. They are reported here as published observations, not as expected effects of any product.

• Developmental retardation in non-human primates. The 2018 Nature study reported that SIRT6 deficiency resulted in developmental retardation in cynomolgus monkeys (PMID 30135584).
• Craniofacial malformation. Researchers reported that Sirt6 loss activated Got1 and facilitated cleft palate through abnormally activated glycolysis (PMID 40050262).
• Impaired nerve repair with pharmacological inhibition. A 2021 study reported that SIRT6 inhibition delayed peripheral nerve recovery by suppressing migration, phagocytosis and M2 polarisation of macrophages (PMID 34906231).
• Worse kidney injury with deficiency. The study reported that Sirt6 deficiency exacerbated podocyte injury and proteinuria (PMID 28871079).

A complementary observation comes from the macrophage work: because SIRT6 influences immune-cell behaviour, researchers reported that suppressing it altered macrophage function during nerve repair (PMID 34906231), which illustrates that modulating a chromatin enzyme in either direction has consequences across multiple cell types.

Limits of the evidence in Module 4

No paper in the verified set recorded adverse events in humans, and none used the standardised safety reporting framework of a clinical trial. Loss-of-function phenotypes describe what happens when an animal develops without the gene; they do not predict the tolerability of any hypothetical SIRT6-targeting intervention, and they say nothing about long-term risk in adults.

Module 5: Pharmacokinetics Where Data Exist

For a conventional drug, this module would summarise absorption, distribution, half-life, metabolism and clearance. For SIRT6, the verified literature does not supply those parameters. The enzyme is produced inside cells and acts within the nucleus, so exposure in these experiments was determined by genetic manipulation, tissue-targeted expression, or the properties of a research tool compound rather than by systemic pharmacokinetics.

What the papers do describe, indirectly, is tissue and compartment specificity. Studies localised SIRT6 activity to defined cell populations — smooth muscle cells in the atherosclerosis work (PMID 33353368), chondrocytes in the osteoarthritis work (PMID 36496445), astrocytes in the demyelination work (PMID 39342313), and retinal ganglion cells and optic nerve in the glaucoma and aging work (PMID 38659223). Subcellular localisation was addressed most directly in the nucleolar remodeling study (PMID 41703428).

Limits of the evidence in Module 5

There is no reported plasma concentration, half-life, bioavailability, route comparison or clearance pathway for a SIRT6-directed agent in the verified papers, and no human pharmacokinetic study appears in this set. Any numerical PK claim about "SIRT6" circulating in the body would not be supported by the sources cited on this page.

Module 6: Regulatory Status, Stated Factually

SIRT6 is a human gene and protein, not a marketed medicine. As of the literature collected here, there is no US Food and Drug Administration–approved drug product whose active ingredient is SIRT6, and none of the verified papers describes an approved SIRT6 therapeutic, a New Drug Application, or an authorised indication. Research materials associated with SIRT6 — recombinant enzyme, antibodies, plasmids, viral vectors and tool compounds that activate or inhibit the enzyme in vitro — are generally distributed as research-use-only (RUO) reagents, meaning they are labelled for laboratory investigation and not for diagnostic or therapeutic administration.

Compounding rules are a separate matter of drug law. In the United States, compounding under sections 503A (traditional pharmacies) and 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act operates around bulk drug substances that meet defined eligibility criteria, such as being the subject of a USP or NF monograph, being a component of an approved drug, or appearing on an FDA-published list. A gene-encoded intracellular enzyme studied in knockout monkeys (PMID 30135584) and rodent disease models (PMID 36278398) does not correspond to an approved or monographed drug substance in these sources. This section is a factual description of regulatory categories and is not legal advice; regulations change and vary by jurisdiction.

Limits of the evidence in Module 6

Regulatory status is a moving target and is determined by agencies, not by journals. The verified papers were written to report biology, not to establish legal classification, so this module reflects general regulatory structure plus the absence of any approval described in the cited work.

What the Studies Did Not Test

Reading the verified set as a whole, the following were outside the scope of the published work:

1. Human efficacy or safety. No paper reported a clinical trial, patient-reported outcomes, or adverse event tables in people; the single non-rodent report was a monkey deficiency model (PMID 30135584).
2. Dose-response. No human dose, frequency or duration appears in these sources, and none of the studies compared dosing schedules in people.
3. Long-term follow-up. The osteoarthritis, atherosclerosis and HFpEF studies used defined experimental windows; researchers reported endpoint measures at study close rather than lifetime outcomes (PMID 36496445, PMID 36278398).
4. Cross-tissue trade-offs. Work showing protection in one tissue, such as the retina (PMID 38659223), did not simultaneously assess whether the same manipulation affected development, immunity or repair elsewhere, an issue highlighted by the nerve-repair inhibition study (PMID 34906231).
5. Interactions. No verified paper examined interactions with prescription medicines, supplements or other interventions in humans.

Taken together, the SIRT6 literature is an active preclinical field describing a chromatin enzyme with broad influence over senescence, metabolism and tissue repair pathways in animal and cell models. It is not, in these sources, a human therapy with established outcomes. Readers with clinical questions should raise them with a licensed physician.

References

• SIRT6 activates PPARα to improve doxorubicin-induced myocardial cell aging and damage (Chemico-Biological Interactions, 2024)
• Sirt6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma (Molecular Therapy, 2024)
• SIRT6 deficiency results in developmental retardation in cynomolgus monkeys (Nature, 2018)
• SIRT6 protects vascular smooth muscle cells from osteogenic transdifferentiation via Runx2 in chronic kidney disease (The Journal of Clinical Investigation, 2022)
• Sirt6 attenuates chondrocyte senescence and osteoarthritis progression (Nature Communications, 2022)
• SIRT6 modulates lesion microenvironment in LPC induced demyelination by targeting astrocytic CHI3L1 (Journal of Neuroinflammation, 2024)
• SIRT6 Protects Smooth Muscle Cells From Senescence and Reduces Atherosclerosis (Circulation Research, 2021)
• Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling (Nature Communications, 2017)
• SIRT6 inhibition delays peripheral nerve recovery by suppressing migration, phagocytosis and M2-polarization of macrophages (Cell & Bioscience, 2021)
• SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes (Circulation Research, 2022)
• SIRT6 Regulates Protein Synthesis and Folding Through Nucleolar Remodeling (Aging Cell, 2026)
• Sirt6 loss activates Got1 and facilitates cleft palate through abnormal activating glycolysis (Cell Death & Disease, 2025)